Yifang Biotech released its 2026 interim report, with net loss attributable to the parent company at 137 million yuan, an increase of 17.649 million yuan compared with the same period last year. Total operating revenue was 53.3192 million yuan, up 178.23% year-on-year, achieving growth for two consecutive years. Net cash outflow from operating activities was 188 million yuan, an increase of 80.6931 million yuan from the same period last year. The company's latest gross margin was 94.44%, asset-liability ratio was 7.30%, and diluted earnings per share was negative 0.24 yuan.
InventisBio Co. Ltd. ANet loss widened to 137 million yuan, though revenue grew 178%.
